MediSpectra’s Luma gains PMA approval
This article was originally published in The Gray Sheet
Executive Summary
A cervical imager that works to identify pre-cancerous cells won PMA approval March 16 from FDA, overcoming last May's 9-2 vote against approving the device from the agency's Obstetrics & Gynecology Devices advisory panel based on concerns about the device's high false positive rate (1"The Gray Sheet" May 23, 2005, p. 11). MediSpectra says when used in conjunction with colposcopy, Luma - the first optical imaging device approved as an aid to clinicians examining women with abnormal Pap tests - identifies sites on the cervix that may contain pre-cancerous cells. FDA's approval was based on data from a study of 193 women that showed Luma detected additional cancer precursors missed by colposcopy...
You may also be interested in...
Ob/Gyn Panel Illuminates Luma Trial Design Problem Areas For MediSpectra
MediSpectra should design and perform a new study to address more closely the specific indication in the firm's PMA for the Luma cervical imager, according to FDA's Obstetrics & Gynecology Devices Panel
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.